Artiva Biotherapeutics is a clinical-stage biotechnology company developing a pipeline of novel, precisely targeted immuno-oncology therapies. The company's proprietary technology platform leverages a deep understanding of the biology of immune cells and their interactions with cancer cells to develop therapies that can selectively activate or suppress immune responses to cancer. Artiva's lead product candidate, AB-101, is a first-in-class, off-the-shelf, allogeneic cell therapy that targets solid tumors by activating natural killer (NK) cells. The company was founded in 2019 and is headquartered in South San Francisco, California.